Profile of elotuzumab and its potential in the treatment of multiple myeloma

Por Liu, Yi-Chang, Szmania, Susann, van Rhee, Frits
Publicado no Blood Lymphat Cancer (2014)

Clinical Grade Purification and Expansion of Natural Killer Cells

Por Lapteva, Natalia, Szmania, Susann M., van Rhee, Frits, Rooney, Cliona M.
Publicado em 2014

Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-...

Por Yi, Qing, Szmania, Susann, Freeman, John, Qian, Jianfei, Rosen, Nancy A., Viswamitra, Sanjaya, Cottler-Fox, Michele, Barlogie, Bart, Tricot, Guido, van Rhee, Frits
Publicado em 2010

Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD010...

Por Moreno-Bost, Amberly, Szmania, Susann, Stone, Katie, Garg, Tarun, Hoerring, Antje, Szymonifka, Jackie, Shaughnessy, John, Barlogie, Bart, Prentice, H. Grant, Van Rhee, Frits
Publicado em 2010

NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses

Por van Rhee, Frits, Szmania, Susann M., Zhan, Fenghuang, Gupta, Sushil K., Pomtree, Mindy, Lin, Pei, Batchu, Ramesh B., Moreno, Amberly, Spagnoli, Guilio, Shaughnessy, John, Tricot, Guido
Publicado em 2005

Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell–mediated lysis of myeloma

Por Shi, Jumei, Tricot, Guido J., Garg, Tarun K., Malaviarachchi, Priyangi A., Szmania, Susann M., Kellum, Rachel E., Storrie, Brian, Mulder, Arend, Shaughnessy, John D., Barlogie, Bart, van Rhee, Frits
Publicado em 2008

Interleukin-6 Receptor Polymorphism Is Prevalent in HIV-negative Castleman Disease and Is Associated with Increased Soluble Interleukin-6 Receptor Levels

Por Stone, Katie, Woods, Emily, Szmania, Susann M., Stephens, Owen W., Garg, Tarun K., Barlogie, Bart, Shaughnessy, John D., Hall, Brett, Reddy, Manjula, Hoering, Antje, Hansen, Emily, van Rhee, Frits
Publicado em 2013

Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation

Por Shi, Jumei, Tricot, Guido, Szmania, Susann, Rosen, Nancy, Garg, Tarun K., Malaviarachchi, Priyangi A., Moreno, Amberly, DuPont, Bo, Hsu, Katharine C., Baxter-Lowe, Lee Ann, Cottler-Fox, Michele, Shaughnessy, John D., Barlogie, Bart, van Rhee, Frits
Publicado em 2008

Ex Vivo Expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo In High-Risk Relapsed Multiple Myeloma Patients

Por Szmania, Susann, Lapteva, Natalia, Garg, Tarun, Greenway, Amy, Lingo, Joshuah, Nair, Bijay, Stone, Katie, Woods, Emily, Khan, Junaid, Stivers, Justin, Panozzo, Susan, Campana, Dario, Bellamy, William T., Robbins, Molly, Epstein, Joshua, Yaccoby, Shmuel, Waheed, Sarah, Gee, Adrian, Cottler-Fox, Michele, Rooney, Cliona, Barlogie, Bart, van Rhee, Frits
Publicado no J Immunother (2015)

Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications

Por LAPTEVA, NATALIA, DURETT, APRIL G., SUN, JIALI, ROLLINS, LISA A., HUYE, LESLIE L., FANG, JIAN, DANDEKAR, VARADA, MEI, ZHUYONG, JACKSON, KIMBERLEY, VERA, JUAN, ANDO, JUN, NGO, MINHTRAN C., COUSTAN-SMITH, ELAINE, CAMPANA, DARIO, SZMANIA, SUSANN, GARG, TARUN, MORENO-BOST, AMBERLY, VANRHEE, FRITS, GEE, ADRIAN P., ROONEY, CLIONA M.
Publicado no Cytotherapy (2012)

Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma

Por van Rhee, Frits, Szmania, Susann M., Dillon, Myles, van Abbema, Anne M., Li, Xin, Stone, Mary K., Garg, Tarun K, Shi, JuMei, Moreno-Bost, Amberly M., Yun, Rui, Balasa, Balaji, Ganguly, Bishwa, Chao, Debra, Rice, Audi G., Zhan, Fenghuang, Shaughnessy, John D., Barlogie, Bart, Yaccoby, Shmuel, Afar, Daniel E.H.
Publicado em 2009

Highly activated and expanded natural killer cells for multiple myeloma immunotherapy

Por Garg, Tarun K., Szmania, Susann M., Khan, Junaid A., Hoering, Antje, Malbrough, Paul A., Moreno-Bost, Amberly, Greenway, Amy D., Lingo, Joshuah D., Li, Xin, Yaccoby, Shmuel, Suva, Larry J., Storrie, Brian, Tricot, Guido, Campana, Dario, Shaughnessy, John D., Nair, Bijay P., Bellamy, William T., Epstein, Joshua, Barlogie, Bart, van Rhee, Frits
Publicado em 2012

CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

Por Hsi, Eric D., Steinle, Roxanne, Balasa, Balaji, Szmania, Susann, Draksharapu, Aparna, Shum, Benny P., Huseni, Mahrukh, Powers, David, Nanisetti, Amulya, Zhang, Yin, Rice, Audie G., van Abbema, Anne, Wong, Melanie, Liu, Gao, Zhan, Fenghuang, Dillon, Myles, Chen, Shihao, Rhodes, Susan, Fuh, Franklin, Tsurushita, Naoya, Kumar, Shankar, Vexler, Vladimir, Shaughnessy, John D., Barlogie, Bart, van Rhee, Frits, Hussein, Mohamad, Afar, Daniel E.H., Williams, Marna B.
Publicado no Clin Cancer Res (2008)